NasdaqGS:ASRT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Assertio Holdings, Inc. operates as a specialty pharmaceutical company in the United States. More Details


Snowflake Analysis

Excellent balance sheet and fair value.


Similar Companies

Share Price & News

How has Assertio Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ASRT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.1%

ASRT

2.0%

US Pharmaceuticals

3.9%

US Market


1 Year Return

-46.1%

ASRT

13.8%

US Pharmaceuticals

18.5%

US Market

Return vs Industry: ASRT underperformed the US Pharmaceuticals industry which returned 12.2% over the past year.

Return vs Market: ASRT underperformed the US Market which returned 17.2% over the past year.


Shareholder returns

ASRTIndustryMarket
7 Day2.1%2.0%3.9%
30 Day-12.5%-1.9%-4.3%
90 Day-18.8%3.4%8.1%
1 Year-46.1%-46.1%16.6%13.8%21.2%18.5%
3 Year-88.8%-88.8%24.4%15.3%38.2%29.0%
5 Year-96.4%-96.4%45.5%28.6%84.3%63.4%

Price Volatility Vs. Market

How volatile is Assertio Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Assertio Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ASRT ($0.67) is trading below our estimate of fair value ($8.59)

Significantly Below Fair Value: ASRT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ASRT is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: ASRT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ASRT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ASRT is good value based on its PB Ratio (0.8x) compared to the US Pharmaceuticals industry average (3x).


Next Steps

Future Growth

How is Assertio Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

119.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ASRT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: ASRT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ASRT's is expected to become profitable in the next 3 years.

Revenue vs Market: ASRT's revenue (1.5% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: ASRT's revenue (1.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ASRT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Assertio Holdings performed over the past 5 years?

-22.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ASRT is currently unprofitable.

Growing Profit Margin: ASRT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ASRT is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.

Accelerating Growth: Unable to compare ASRT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ASRT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: ASRT has a negative Return on Equity (-214.84%), as it is currently unprofitable.


Next Steps

Financial Health

How is Assertio Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: ASRT's short term assets ($135.5M) exceed its short term liabilities ($134.4M).

Long Term Liabilities: ASRT's short term assets ($135.5M) exceed its long term liabilities ($126.4M).


Debt to Equity History and Analysis

Debt Level: ASRT's debt to equity ratio (111.1%) is considered high.

Reducing Debt: ASRT's debt to equity ratio has reduced from 230.9% to 111.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ASRT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ASRT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 38.5% per year.


Next Steps

Dividend

What is Assertio Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ASRT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ASRT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ASRT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ASRT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ASRT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Todd Smith (50 yo)

0.33

Tenure

Mr. Todd N. Smith served as President, Chief Executive Officer and Director at Zyla Life Sciences since October 22, 2019. Mr. Smith serves as Chief Executive officer, President and Director at Assertio Hol ...


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Peisert
Executive VP & CFO1.75yrsUS$1.61m0.11%
$ 75.0k
Todd Smith
CEO, President & Director0.33yrno data0.60%
$ 429.3k
Mark Strobeck
Executive VP & COO0.33yrno data0.23%
$ 165.5k
E. Clark-Schoeb
Media & Investor Relations Officerno datano datano data
Megan Timmins
Senior VP0.33yrno data0.18%
$ 126.8k
Sarah Longoria
Vice President of Human Resources0.33yrno datano data
Max Nemmers
Director of Human Resourcesno datano datano data

0.3yrs

Average Tenure

48.5yo

Average Age

Experienced Management: ASRT's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Todd Smith
CEO, President & Director0.33yrno data0.60%
$ 429.3k
Peter Staple
Independent Director16.83yrsUS$285.74k0.21%
$ 147.6k
William McKee
Independent Director3.5yrsUS$290.59k0.063%
$ 45.2k
Arthur Higgins
Non-Executive Chairman0.33yrUS$4.87m0.39%
$ 281.4k
James Tyree
Independent Director3.92yrsUS$270.65k0.075%
$ 53.6k
Heather Mason
Independent Director1.58yrsUS$259.59k0.013%
$ 9.6k
Timothy Walbert
Lead Independent Director0.33yrno data0.046%
$ 32.7k
David Wheadon
Independent Director1yrUS$206.75kno data
Andrea Smiley
Director0.33yrno data0.046%
$ 32.7k

1.0yrs

Average Tenure

59yo

Average Age

Experienced Board: ASRT's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.9%.


Top Shareholders

Company Information

Assertio Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Assertio Holdings, Inc.
  • Ticker: ASRT
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$71.311m
  • Shares outstanding: 107.12m
  • Website: https://www.assertiotx.com

Number of Employees


Location

  • Assertio Holdings, Inc.
  • 100 South Saunders Road
  • Suite 300
  • Lake Forest
  • Illinois
  • 60045
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ASRTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 1997
AH3DB (Deutsche Boerse AG)YesCommon StockDEEURDec 1997

Biography

Assertio Holdings, Inc. operates as a specialty pharmaceutical company in the United States. Its specialty pharmaceutical products include CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for treatin ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/01 00:01
End of Day Share Price2020/09/30 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.